Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer and advances in its clinical and laboratory biology have grown exponentially over the last few decades. Treatment outcome has improved steadily with over 90% of patients surviving 5 years from initial diagnosis. This success can be attributed in part to the development of a risk stratification approach to identify those subsets of patients with an outstanding outcome that might qualify for a reduction in therapy associated with fewer short and long term side effects. Likewise, recognition of patients with an inferior prognosis allows for augmentation of therapy, which has been shown to improve outcome. Among the clinical and biological variables known to impact prognosis, the kinetics of the reduction in tumor burden during initial therapy has emerged as the most important prognostic variable. Specifically, various methods have been used to detect minimal residual disease (MRD) with flow cytometric and molecular detection of antigen receptor gene rearrangements being the most common. However, many questions remain as to the optimal timing of these assays, their sensitivity, integration with other variables and role in treatment allocation of various ALL subgroups. Importantly, the emergence of next generation sequencing assays is likely to broaden the use of these assays to track disease evolution. This review will discuss the biological basis for utilizing MRD in risk assessment, the technical approaches and limitations of MRD detection and its emerging applications.
Pediatric moderate aplastic anemia (MAA) lacks defined diagnostic criteria and a clear standard-of-care due to the limited knowledge of its pathophysiology and natural history. The approach to MAA has been historically inconsistent as the proposed survey demonstrates. To understand current diagnostic and management practices for patients with MAA, a survey was conducted among members of the North American Pediatric Aplastic Anemia Consortium (NAPAAC), including 104 providers across 57 institutions. The survey demonstrates broad variability regarding the working definition, diagnostic work-up, and therapeutic management of children with MAA. The diagnostic work-up and treatment options for children with MAA are largely driven by management guidelines for pediatric severe aplastic anemia (SAA). Treatment triggers, type of therapy, and outcomes varied widely among respondents. Curated next generation sequencing panels and whole exome/whole genome sequencing were included by only 55% and 9% of respondents, respectively which suggests the need to more broadly consider inherited bone marrow failure syndromes in the differential diagnosis for these patients. Effective and risk-adapted treatment for MAA requires a better understanding of the biology, natural history, and treatment outcomes for this heterogeneous population.